

# MYELOFIBROSIS

Myelofibrosis is a rare form of blood cancer that causes scar tissue to build up in the bone marrow, which is the soft, fatty tissue inside most bones that produces blood cells. Myelofibrosis belongs to a group of conditions known as myeloproliferative neoplasms (MPNs). Myelofibrosis can develop on its own (known as primary myelofibrosis), but in 15 to 20 percent of cases this cancer occurs as a result of other MPNs (called secondary myelofibrosis).

## Common Symptoms and Signs

 <p>Fatigue and shortness of breath</p>	 <p>Decreased appetite, weakness, pale skin, and fever</p>	 <p>Bruising and/or bleeding</p>	 <p>Abdominal discomfort, spleen or liver enlargement</p>
 <p>Night sweats</p>	 <p>Itching</p>	 <p>Frequent infections</p>	 <p>Bone or joint pain</p>

## Risk Factors

The cause of myelofibrosis is unknown, but researchers have identified several risk factors for the disease.

<p>Myelofibrosis is diagnosed most often in people over</p> <h1>Age 50</h1> <p>White people have a greater risk for myelofibrosis than people of other races.</p>	 <p><b>Having other blood disorders</b> People who have the blood diseases thrombocythemia or polycythemia vera have an increased risk for myelofibrosis.</p>	 <p><b>Exposure to radiation</b> A history of exposure to radioactive material is associated with an increased risk for MF.</p>
 <p><b>Exposure to petrochemicals</b> A history of exposure to radioactive material is associated with an increased risk for myelofibrosis.</p>	<h1>90%</h1> <p>of myelofibrosis patients have mutations in the JAK2, CALR, or MPL genes.</p>	

## Who Gets Myelofibrosis?

 <p>The median age at diagnosis of myelofibrosis is</p> <h1>65</h1>	<h1>1.5 times</h1> <p>Men are 1.5 times more likely than women to be diagnosed with myelofibrosis.</p> 
--	--

This blood disorder is more common in people of certain heritages, including Ashkenazi Jews.




Scan the QR Code to learn more about Massive Bio

## How Common is Myelofibrosis?

Myelofibrosis is a rare disease. The incidence is estimated to be 1.5 cases per 100,000 people in the United States. In studies of Northern European countries, the incidence was estimated to be 0.5 cases per 100,000 people.

● 1.5 cases per 100,000 people

● 0.5 cases per 100,000 people



## We Believe

All people should have equal access to leading-edge therapies and new emerging clinical trials, regardless of where they live or their ability to pay.

We are committed to keeping referring physicians updated through HIPAA-compliant communication. Additionally, we will appropriately and deliberately transition patients back into your care upon trial completion.

Our AI technology will screen and match patients to clinical trials in the following disease types:

- Solid tumors (carcinoma)
- Sarcoma
- Myeloma
- Leukemia
- Lymphoma
- Mixed types
- Any malignancy with a biomarker or gene mutation



Estimated number of clinical trials of myelofibrosis that are recruiting or in preparation.

# 110



Scan the QR Code to learn more about Massive Bio